---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000016"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:33:24.775540+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio reports IBIO-600 NHP half-life up to 52 days; Activin E antibody shows 34% weight loss with semaglutide

## Summary
- IBIO-600 NHP half-life 40-52 days; estimated human half-life up to 130 days, enabling once every 3-6 month dosing.
- IBIO-600 promoted dose-dependent lean mass increase (3.1% low-dose, 5.1% high-dose) and fat reduction in NHPs after 8 weeks.
- Activin E antibody monotherapy in obese mice: 4% weight loss, 18% total body fat reduction vs placebo after 2 weeks.
- Activin E antibody combined with semaglutide: 34% total weight loss, 72% fat reduction – synergistic beyond GLP-1 alone.
- iBio on track for IBIO-600 regulatory submission in Q1 2026.

## SEC filing metadata
- accession: 0001420720-25-000016
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000016/0001420720-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000016/ibio-20250407x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000016
- JSON: https://secwatch.observer/filing/0001420720-25-000016.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.